MétaCan
Menu
Back to cohort
Record W4312087911 · doi:10.1002/alz.063660

Boswellic acids (K‐Vie<sup>™</sup>) improves clinical cognitive scores and reduces systemic inflammation in patients with mild to moderate Alzheimer’s disease.

2022· article· en· W4312087911 on OpenAlexaff
Saeed Karima, Vajiheh Aghamollaii, Abbas Tafakhori, Somayeh Mahmoodi Baram, Laurent Balenci, Krista L. Lanctôt, Alexander Kiss, Meisam Mahdavi, Shima Rajaei, Somayeh Shateri, Farzad Mokhtari, Akbar Fotouhi, Ali Riazi

Bibliographic record

VenueAlzheimer s & Dementia · 2022
Typearticle
Languageen
FieldMedicine
TopicPharmacological Effects of Medicinal Plants
Canadian institutionsSunnybrook HospitalSunnybrook Health Science Centre
Fundersnot available
KeywordsPlaceboMedicineInternal medicineBoswellia serrataGastroenterologyRandomized controlled trialClinical trialPathology

Abstract

fetched live from OpenAlex

Abstract Background Alzheimer’s disease (AD) remains an incurable neurodegenerative disorder. Neuroinflammation has been now recognized as an important player in the pathogenesis of AD. We conducted a clinical trial to measure whether boswellic acids (K‐Vie™, an enriched Boswellia extract) can improve cognitive and neuropsychiatric symptoms while reducing inflammation in patients with AD. Method We conducted a placebo‐controlled clinical trial including a total of 85 patients with mild‐to‐moderate (based on MMSE) Alzheimer’s disease randomized to Boswellia (n = 43) and placebo (n = 42) groups. The treatment doses were 400 mg K‐Vie™ capsule, thrice a day (1200 mg/day), versus matching placebo. Result Of 85 patients, 43 were assigned to Boswellia and 42 to the placebo group. There were 8 dropouts. The median age of study participants was ∼71 (range, 63‐85) for the Boswellia and ∼70 (range, 61‐81) for the placebo group with 54.5% females and 45.5% males. After 6 months of treatment, there was a significant increase of the MMSE scores with a 1.7 (df = 39, 95% CI 1.2 to 2.1) unit in the Boswellia group compared to ‐1.4 (df = 36, 95% CI ‐2.0 to ‐0.9) unit decrease in the placebo group. There was also a significant decrease of the CDR‐SOB scores in the boswellia group with ‐0.8 (df = 39, 95% CI ‐1.1 to ‐0.6) unit difference, whereas the placebo group saw a 0.8 (df = 36, 95% CI 0.4 to 1.2) unit increase from baseline to 6 months. The analysis of neuropsychiatric symptoms (NPI‐Q) revealed a significant ‐3.4 (df = 27, 95% CI ‐6.1 to ‐0.8) unit decrease, whereas the placebo group did not show a significant change (p = 0.08) (df = 23, 95% CI ‐0.4 to 6.9). Patients receiving Boswellia showed a significant decrease as compared to placebo in plasma levels of several key pro‐inflammatory cytokines including IL‐6 (F(1,38) = 71.1, p&lt;0.0001), TNF‐α (F(1,35) = 14.8, p = 0.0005), and IL‐1α (F(1,38) = 33.4, p&lt;0.0001) as well as a significant increase in the plasma level of amyloid‐β42/amyloid‐β40 ratio (F(1,36) = 19.3, p&lt;0.0001). No serious adverse events were observed during the trial. Conclusion This study suggests that a reduction of systemic inflammatory biomarkers correlates with improvement in brain and cognitive function. Decreasing inflammation may represent a novel avenue to effectively treat AD.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.175
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.034
GPT teacher head0.319
Teacher spread0.285 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & DementiaSame topicPharmacological Effects of Medicinal PlantsFrench-language works237,207